Keratan sulfate expression in microglia is diminished in the spinal cord in experimental autoimmune neuritis

H Matsui1,2,5, T Ohgomori1,5, T Natori3,5, K Miyamoto4, S Kusunoki4, K Sakamoto1, N Ishiguro2, S Imagama*2 and K Kadomatsu*,1

Experimental autoimmune neuritis (EAN) is an animal model of Guillain–Barre syndrome, an inflammatory demyelination disease of the peripheral nervous system. Although this disease has been extensively studied on peripheral nerves, the pathology of the central nervous system has not been fully understood. Previous studies demonstrate that expression of keratan sulfate (KS), the sugar chain of proteoglycan, is associated with activated microglia/macrophages accumulated after neuronal injuries. Unexpectedly, we found here that KS is rather diminished in rat EAN. KS was restrictively expressed in microglia in the spinal cord of normal rats. KS was positive in 50% microglia in the ventral horn and 20% in the dorsal horn. In EAN, microglia increased in number and expressed the activation marker CD68, but KS expression was abolished. Concomitantly, pro-inflammatory cytokines, i.e., interferon (IFN)-γ, interleukin (IL)-1β, and tumor necrosis factor (TNF)-α, were increased in the spinal cord of EAN rats, whereas anti-inflammatory cytokines, such as IL-4 and IL-10, were decreased. In addition, silencing of KSGal6ST attenuated KS expression on the primary cultured microglia and upregulated expression of some activation markers (TNF-α, IL-1β, and iNOS) under the stimulation with lipopolysaccharide and IFN-γ. This study demonstrates for the first time a close association of EAN and disappearance of KS on microglia. KS expression could be a useful marker to evaluate the status of polyneuropathy.

Received 27.5.13; revised 29.10.13; accepted 05.11.13; Edited by A Verkhratsky

Citation: Cell Death and Disease (2013) 4, e946; doi:10.1038/cddis.2013.479; published online 5 December 2013

Subject Category: Neuroscience

Experimental autoimmune neuritis is an animal model of human Guillain–Barre syndrome, and is a helper T-cell-mediated inflammatory demyelination disease in peripheral nerve that is affected by the immunization of P2 peptide. The pathology of peripheral nerves in EAN has been extensively studied; EAN involves disruption of blood nerve barrier, infiltration of T cells and macrophages, leakage of immunoglobulin, and regional demyelination. Although the central nervous system (CNS) has been poorly studied on EAN, some important findings on CNS have been reported. Microglia transiently increase in number and they express P2X4 receptor involved in allodynia and pain hypersensitivity in the dorsal horn of the spinal cord in EAN. Moreover, infiltration of CD4-positive T cells is observed in the spinal cord and triggers apoptosis of motor neurons.

Proteoglycans (PGs) have long sugar chains, so-called glycosaminoglycans, i.e., chondroitin sulfate, keratan sulfate (KS), dermatan sulfate, and heparan sulfate. KS is a polymer of lactosamine, 3Gal[b1–4GlcNAc]/1, sulfated at the C6 position of GlcNAc residue, which is an essential step for KS biosynthesis. Therefore, GlcNAc6ST-1-deficient mice show loss of KS in the CNS. We and others reported that KS expression is enhanced in microglia/macrophages and the extracellular matrix after spinal cord injury (SCI). We found that GlcNAc6ST-1 mice show better functional recovery after SCI. Ablation of KS with its degrading enzyme keratanase II also promotes functional recovery after SCI. Further in vitro studies revealed that KS in extracellular matrix has an inhibitory role in axonal regeneration/sprouting that is relevant to functional recovery with KS ablation after SCI. On the other hand, the biological significance of KS expressed in microglia/macrophages remains obscure.

In this study, we attempted to clarify the pathology of the CNS in EAN. We particularly focused on KS expression. Based on an association of KS expression and activated microglia/macrophages accumulated after neuronal injuries, we had speculated that KS expression might be upregulated in the spinal cord to exacerbate EAN. However, we found that KS was rather diminished in rat EAN. We have revealed for the first time the relationship of KS expression and EAN pathogenesis.

1Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; 2Department of Orthopedics, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan; 3Department of Health and Nutrition, Yamanashi Gakuin University, Kofu 400-8575, Japan and 4Department of Neurology, Kinki University School of Medicine, Sayama, Osaka 589-8511, Japan

*Corresponding authors: S Imagama or K Kadomatsu, Departments of Biochemistry and Orthopedics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan. Tel: +81 52 468 2058; Fax: +81 52 744 2065; E-mail: imagama@med.nagoya-u.ac.jp or kkadoma@med.nagoya-u.ac.jp

These authors contributed equally to this work.

Keywords: experimental autoimmune neuritis; keratan sulfate; microglia

Abbreviations: CFA, complete Freund's adjuvant; CNS, central nervous system; EAN, experimental autoimmune neuritis; IFN, interferon; IL, interleukin; KS, keratan sulfate; LFB, luxol fast blue; LPS, lipopolysaccharide; PBS, phosphate-buffered saline; PFA, paraformaldehyde; PG, proteoglycan; SCI, spinal cord injury; TNF, tumor necrosis factor

Received 27.5.13; revised 29.10.13; accepted 05.11.13; Edited by A Verkhratsky
Results

The expression of KS is diminished in the spinal cord of EAN. The clinical scores of control (complete Freund’s adjuvant (CFA) alone: open circles) and EAN (closed circles) rats were shown in Figure 1a. The symptom of limp tail first appeared at 9 days after immunization and this point was defined as onset of EAN. The peak of symptoms was observed at 14–18 days and subsequently recovered at 25 days. No symptoms were observed in control rats. The histological analysis revealed that inflammatory cells strikingly infiltrated in the sciatic nerve (SN) at the peak of EAN (18 days after immunization) (Figure 1b, hematoxylin and eosin (H&E) staining). Demyelination of SNs was also observed in EAN (Figure 1b, Luxol Fast Blue (LFB) staining). On the other hand, infiltrated inflammatory cells and demyelination were not observed in control rats (Figure 1b).

The expression levels of KS in the spinal cord of control and EAN rats were analyzed by immunoblotting at the peak of EAN. The KS-specific antibody 5D4 was used in this experiment. Tissues were obtained from the cervical, thoracic, thoraco–lumbar and lumbar spinal cord, and SNs (Figure 2). KS was detected at the size of 150–250 kDa in all regions of the control spinal cords (Figure 2, lanes 1, 3, 5, and 7). As KS is a long sugar chain, KS-bearing PGs appear as smear bands as shown in Figure 2. Surprisingly, this reactivity disappeared in EAN (Figure 2, lanes 2, 4, 6, and 8). In contrast, KS could not be detected in SNs of both control and EAN rats (Figure 2, lanes 9 and 10).

KS is specifically expressed in a subpopulation of microglia in normal spinal cord. We next attempted to identify the source of KS expression. The KS-positive cells were a part of Iba1-positive microglia/macrophages in the spinal cord of normal rats (Figure 3a). Although the number of microglia/macrophage significantly increased at the peak of EAN, KS expression disappeared (Figure 3a). The morphology of microglia/macrophage was changed from ‘ramified’ to ‘amoeboid’ shape in the spinal cord of EAN, indicating that these microglia/macrophages were activated. In addition, we used CD11b (OX-42) as an additional marker for microglia/macrophages and found that expressions of Iba1 and CD11b were almost completely merged (Figure 3b). Therefore, all the Iba1-positive cells were CD11b positive. These data suggested that a subpopulation of microglia/macrophages expressed KS in normal spinal cord.

The number of Iba1-positive cells was increased in both ventral and dorsal horns at the peak of EAN (Figure 3c), consistent with a previous report. Iba1-positive microglia/macrophage predominantly increased in spinal cord dorsal horn. In normal spinal cords, the ratio of KS-positive microglia in Iba1-positive cells was significantly higher in the ventral horn (49 ± 8.9%) than in dorsal horn (20 ± 3.7%) (Figure 3d). KS expression was disappeared in both dorsal and ventral horns at the peak of EAN (Figure 3d).

Spatio-temporal relationship of KS and microglia/macrophages activation markers. We next examined the relationship between KS expression and microglia/macrophages activation in the context of the progression of EAN. KS could be detected in the spinal cord in pre-onset phase (4–7 days after immunization), and disappeared at onset (12 days), peak (18 days), and remission (35 days) phases (Figure 4, top panel). This reactivity was partially recovered at 90 days after immunization (Figure 4, top panel, lane 12). The expression level of the microglia/macrophage marker

![Figure 1](https://example.com/fig1.png)  
**Figure 1** Clinical scores of EAN and pathological changes of SNs. (a) The clinical scores of control and EAN rats were evaluated every day after immunization of CFA and P2 peptide (n = 15 per each groups). (b) The SNs of control and EAN rats were stained by H&E and LFB staining. Infiltration of inflammatory cells and demyelination were observed at the peak of EAN. Scale bars, 50 μm

![Figure 2](https://example.com/fig2.png)  
**Figure 2** Expression of KS is abolished at the peak of EAN. KS expression was examined with the KS-specific antibody 5D4 for spinal cords and SNs of control and EAN rat. SCC, spinal cord cervical, SCT, spinal cord thoracic, SCTL, spinal cord thoraco–lumbar, SCL, spinal cord lumbar. β-actin was used as the internal loading control.
Iba1 significantly increased at 12 and 18 days, showing a mirror image of KS expression (Figure 4, second panel). It is known that activated microglia has two phenotypes, i.e., ‘classically activated’ microglia (M1) and ‘alternatively activated’ microglia (M2). In general, M1 microglia/macrophages exert pro-inflammatory functions, whereas M2 microglia/macrophages show anti-inflammatory functions. Activation markers detected by antibodies available for rat microglia include CD68 and CD206. CD68 is usually induced upon activation and may be positive for both M1 and M2 microglia, whereas CD206 exclusively represent a subset of M2 microglia. We found that both CD68 and CD206 were strongly expressed during EAN, showing a mirror image of KS expression (Figure 4, third and fourth panels).

**Figure 3** KS is specifically expressed on microglia/macrophages in the normal spinal cord. (a) The spinal cord frozen sections were from control or EAN rats and were stained with indicated antibodies. Scale bars, 20 μm. The figure shows the representative images in the dorsal horn area of control and EAN rats. (b) Iba1-positive cells were completely merged with CD11b-positive cells in the normal spinal cords. Scale bars, 20 μm. (c) The number of Iba1-positive cells was counted in the ventral and dorsal horns of the normal and EAN spinal cords (n = 10). (d) The percentages of KS-positive cells were calculated in ventral and dorsal horns of the normal and EAN spinal cords. The numbers in parentheses indicate the number of microglia examined. Each column represents average ± S.D. N.D., not detected. The P-value was calculated using Student’s two-tailed t-test. **P < 0.01

**Figure 4** Reverse relationship of KS and microglia/macrophages activation markers. Expression of KS, Iba1, CD68, and CD206 was examined at 4, 7, 12, 18, 35, and 90 days after the immunization. β-actin was used as the internal loading control.

Iba1 significantly increased at 12 and 18 days, showing a mirror image of KS expression (Figure 4, second panel). It is known that activated microglia has two phenotypes, i.e., 'classically activated' microglia (M1) and 'alternatively activated' microglia (M2). In general, M1 microglia/macrophages exert pro-inflammatory functions, whereas M2 microglia/macrophages show anti-inflammatory functions. Activation markers detected by antibodies available for rat microglia include CD68 and CD206. CD68 is usually induced upon activation and may be positive for both M1 and M2 microglia, whereas CD206 exclusively represent a subset of M2 microglia. We found that both CD68 and CD206 were strongly expressed during EAN, showing a mirror image of KS expression (Figure 4, third and fourth panels).

Immunohistochemical analysis revealed that microglia expressed KS but not CD68 in normal spinal cords (Figure 5a). In EAN, CD68 expression was induced and overlapped in Iba1-positive cells (Figure 5b). To further confirm the immunohistochemical findings, we enriched immune cells from the spinal cord. Immune cells purified from normal spinal cords using Percoll gradient expressed...
5D4-reactive KSPGs, the molecular weights of which ranged 150–250 kDa on immunoblotting, and were consistent with those of original tissue lysate of normal spinal cords (Figure 6a, first and second lanes; compared with Figures 2 and 4). This KS expression was diminished at the peak of EAN (Figure 6a, third lane). Thus, these biochemical data were consistent with the immunohistochemical findings as shown in Figures 3 and 5.

We further investigated immune cells purified from the spinal cords by Percoll gradient. Most of the purified cells were negative of 7-amino-actinomycin D, suggesting that these are living cells (Figure 6b, upper panels). Using these living cells, flow cytometry analyses for CD11b, CD45, and KS were performed. In SNs, there were mainly two populations: CD11b-CD45+ cells (lymphocytes; Figure 6b, gate A) and CD11b+CD45+ cells (macrophages; Figure 6b, gate B). The latter dominantly contains CD11b+CD45high cells. Both the two populations increased in number in EAN (Figure 6b, lower panels; Figure 6c). There were also two main populations, i.e., CD11b-CD45+ lymphocytes (gate A) and CD11b+CD45+ microglia/macrophages (gate B) in the spinal cords, and both the two populations increased in number in EAN (Figure 6b, lower panels; Figure 6d). The CD11b+CD45+ cells in EAN spinal cords (gate B) may contain CD11b+CD45low microglia and CD11b+CD45high-activated microglia/peripheral macrophages. Indeed, CD45 expression was significantly increased in microglia/macrophages in EAN (Figures 6e and f).

We found that KS intensity was significantly decreased in CD11b+CD45+ microglia/macrophages in EAN spinal cords (Figures 6g and h). KS-positive microglia/macrophages were also strikingly reduced in number in EAN spinal cords (Figures 6g and i). In contrast, both CD11b-CD45+ lymphocytes (gate A) and CD11b+CD45+ macrophages (gate B) in SNs were KS negative (Figure 6j). Taken together, KS was specifically expressed on microglia/macrophages and disappeared in activated ones at the peak of EAN.

Expression of pro-inflammatory cytokines are upregulated in the spinal cord of EAN. The expression status of microglia/macrophages is influenced by pro-inflammatory and anti-inflammatory cytokines. We next asked what cytokines were produced in the spinal cord of EAN. We found that expression of pro-inflammatory cytokines, such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ, was increased in EAN (Figure 7a), whereas anti-inflammatory cytokines, including IL-4 and IL-10, were less expressed in EAN (Figure 7b).

Expression of microglia/macrophages activation markers is upregulated by the knockdown of KSGal6ST. KS expression was observed in the primary cultured microglia. The M1-polarizing stimulus lipopolysaccharide (LPS) + IFN-γ alone could not diminish KS, rather appeared to upregulate KS. KSGal6ST is an essential enzyme for the biosynthesis of highly sulfated KS, which is recognized by the antibody 5D4. As expected, the 5D4-reactive epitopes were diminished after the knockdown of KSGal6ST under both non-treated and LPS/IFN-γ-stimulated conditions (Figure 8a). Importantly, the production of pro-inflammatory cytokines, such as TNF-α and IL-1β, was more upregulated by KSGal6ST knockdown under LPS/IFN-γ stimulation (Figures 8b and c). Furthermore, mRNA expression of the M1 marker iNOS was significantly upregulated after KSGal6ST knockdown (Figure 8d, columns 1 and 3). The expression of iNOS was elevated by the stimulation of LPS and IFN-γ, where KSGal6ST knockdown further accelerated the elevation (Figure 8d, columns 2 and 4). These in vitro expression profiles of markers were consistent with those observed in vivo as shown in Figures 4 and 7.

Discussion

We revealed in this study the reverse relationship between KS expression and progression of EAN. Immunoblotting, immunohistochemistry, and flow cytometric analyses
clearly demonstrated that KS expression in microglia/macrophages was lost from onset to remission stages of EAN. Although further studies are required to establish the usefulness of KS expression in human polyneuropathy, our study demonstrates that KS is a good marker for rat EAN.

We also found an interesting relationship of expressions of KS and microglia/macrophages activation markers. Microglia acquired CD68 expression, a general activation marker of microglia, during EAN, when KS expression was lost. It is obscure whether KS-positive cells switched to CD68-positive cells or KS-negative cells gave rise to CD68-positive cells. However, at least, the inflammatory milieu in the spinal cord in EAN may be important for expression changes of those markers. Thus, various inflammatory cytokines and chemokines are upregulated in the spinal cord after the
onset of EAN. A previous report demonstrates that granulocyte/macrophage colony-stimulating factor or TNF-α increases KS expression in cultured microglia. Indeed, if either factor is combined with IFN-γ, KS expression is strikingly suppressed. Indeed, we found that IFN-γ and TNF-α are both induced in the spinal cord of EAN (Figure 7). Interestingly, we also found that anti-inflammatory cytokines, i.e., IL-4 and IL-10 were suppressed in EAN. In this context, it is noteworthy that KS expression is enhanced in the spinal cord after SCI of rats and mice.14–16 KS expression is also induced in a cortical stab wound of mice and SOD1G93A mice, a model of amyotrophic lateral sclerosis.13,22,23 Therefore, expression profiles and biological roles of KS may differ depending on inflammatory milieu in the CNS.

Regarding the role of KS in EAN, we performed experiments of KS knockdown in primary cultured microglia. We found that LPS + IFN-γ strikingly increased the production of TNF-α and IL-1β, as well as mRNA expression of iNOS, and that KSGal6ST knockdown enhanced these increases (Figure 8). Therefore, KS-less microglia were more sensitive to inflammatory stimuli; this is consistent with the in vivo findings of the association of EAN and diminished expression of KS in microglia/macrophages. However, further studies are required for the evaluation of the role of KS in microglia/macrophages in EAN. In addition, there is an alternative possibility that the diminished KS expression might be a consequence of inflammation. Thus, we previously revealed the upregulation of proteases in the injured spinal cord. As the KSPGs are expressed on the cell surface of microglia in control rat, the upregulated proteases might degrade the core protein of KSPGs.

Although EAN is a representative model for autoimmune diseases of peripheral neurons, experimental autoimmune encephalomyelitis is a representative model for autoimmune diseases of the CNS and is a model for human multiple sclerosis. It has been reported that KS is down-regulated in experimental autoimmune encephalomyelitis. Furthermore, microRNA-124 promotes microglia quiescence and suppresses experimental autoimmune encephalomyelitis. MicroRNA-124 also downregulates pro-inflammatory cytokines and M1 markers (e.g., TNF-α, CD86, and nitric oxide) and upregulates anti-inflammatory cytokines and M2 markers (e.g., TGF-β1, arginase 1, and FIZZ1). Furthermore, it has been recently reported that various microRNAs including miR-27a, -29b, -125a, -146a -155, and -222 are implicated in polarized phenotypes of macrophages. Investigations on microRNAs in EAN might provide a clue to reveal the biological role of KS in this disease.

In summary, we found an interesting reverse relationship between KS expression and EAN pathogenesis, as well as microglial activation. Taken together previous reports of KS expression and functional recovery after neuronal injuries, our present study suggest that distinct inflammatory milieu in the CNS may determine expression profiles and biological roles of KS.

**Materials and Methods**

**Animals and EAN induction.** Male Lewis rats (ages: 8–10 weeks, 200–300 g; Japan SLC, Shizuoka, Japan) were housed under a 12-h light–12-h dark cycle with free access to food and water for 1 week. The institutional animal care and use committees of Nagoya University Graduate School of Medicine approved all experimental procedures. Rats were immunized in the hind footpad with 200 μl of inoculum containing 100 μg of synthetic P2 peptide (NH2-RTESTKNTIESSPKLGEFEETTAAD-COOH), representing amino acid residues 53–78 of human myelin P2 protein (TORAY, Tokyo, Japan). The peptide was dissolved in phosphate-buffered saline (PBS; 1 mg/ml) and then emulsified with an equal volume of CFA (Difco, Detroit, MI, USA) containing 1 mg/ml mycobacterium tuberculosis H37 Ra to get a final concentration of 0.5 mg/ml. Control rats were immunized with 200 μl of inoculum containing PBS and CFA. Neurological symptoms of EAN were evaluated every day as follows: 0, normal; 1, limp tail; 2, abnormal gait; 3, mild paralysis; 4, moderate paralysis; and 5, complete paralysis.30 Control and EAN rats were perfused intracardially with 4% paraformaldehyde (PFA) followed by PBS under anesthesia, and the cervical, thoracic, thoraco–lumbar, lumbar spinal cords, and SNs were quickly isolated at 4, 7, 12, 18, 35, and 90 days after immunization. In order to evaluate the histological findings after the EAN induction, H&E and LFB staining was performed in those SNs. The paraffin-embedded sections were stained by LFB solution (0.1% LFB MBS and 0.05% acetic acid containing in 95% ethanol) overnight at 56 °C. After washing, the sections were briefly rinsed by 0.05% LiCO3 and 70% ethanol. After the rinsing with distilled water, the sections were incubated in Cresyl violet solution to stain the neurons for 6 min. After several washing, the sections were mounted with Eukitt (AS ONE, Osaka, Japan) and examined by an Olympus model BX41 microscope (Olympus, Melville, NY, USA).

**Western blotting.** Spinal cords and SNs were homogenized in the lysis buffer (protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan) and 1% Triton X-100 in PBS) at 4 °C for 60 s. The homogenates were centrifuged at 20,000 g for 15 min, and then the soluble protein concentrations were measured by Bradford protein assay using Protein Quantification Kit (Dojindo, Tokyo, Japan). The soluble proteins were treated with chondroitinase ABC (1 U/ml; Seikagaku Corporation, Tokyo, Japan) in 50 mM Tris-acetate buffer (pH 8.0) at 37 °C for 1 h and 20 μl of 2 × SDS-PAGE sample buffer (0.125 M Tris-HCl, pH 6.8; 10% 2-mercaptoethanol; 4% SDS; 10% sucrose; 0.004% bromophenol blue) was added. The samples were subjected to SDS-PAGE after the boiling for 10 min. After transferring the proteins to a polyvinylidene difluoride membrane (Hybond-P; GE Healthcare, Uppsala, Sweden) and blocking it with PBS-T containing 5% skimmed milk, the membrane was blotted by mouse anti-KS antibody (1:1000; clone SD4, Seikagaku Corporation), rabbit anti-β-actin antibody (1:1000; Chemicon International, Temecula, CA) and mouse anti-TNF-α antibody (1:1000; Santa Cruz, CA).
Figure 8  KSGal6ST knockdown attenuates the KS expression in primary cultured microglia and induces significantly higher expression of microglia/macrophages activation markers. (a) Total cell lysates of cultured microglia were subjected to immunoblotting with the anti-KS (5D4) and anti–β-actin antibodies. The concentration of the inflammatory cytokines (TNF-α (b) and IL-1β (c)) in the culture media was measured by ELISA kit purchased from R&D Systems (Minneapolis, MN, USA). (d) mRNA expression of iNOS, a classically activated 'M1' marker. Quantitative real-time PCR was performed to estimate mRNA expression. Each column represents average ± S.D. The P-value was calculated using Student’s two-tailed t-test. *P<0.05, **P<0.01; n = 3

Immunohistochemistry. Isolated spinal cords were fixed with 4% PFA in phosphate buffer (Wako) overnight, and cryoprotected by immersion in 20% sucrose in PBS during the subsequent night. The tissue samples were embedded in Tissue-Tek O.C.T. compound (Sakura Finetek, Tokyo, Japan) and quickly frozen by liquid nitrogen. Frozen tissues were cut into 20 μm sections on a cryostat (CM1800; Leica Instruments, Nussloch, Germany) and collected on MAS-coated glass slides (Superfrost; Matsunami Glass, Osaka, Japan). The sections were triple rinsed with PBS to wash out the cryoprotectant and fixed with 4% PFA in phosphate buffer, and permeabilized with PBS containing 0.1% Triton X-100. After blocking with 3% bovine serum albumin in PBS containing 0.1% Triton X-100, the sections were treated with chondrotinase ABC (0.5 U/ml) at 37°C for 1 h, and then incubated with primary antibodies as follows; mouse anti-KS (1:200), rabbit anti-Iba1 for microglia/macrophages (1:200), mouse anti-CD68 for activated microglia/macrophages (1:200), and mouse anti-CD11b for microglia/macrophages (1:200; Biolegend, San Diego, CA, USA). After triple rinsing with PBS, the sections were incubated with secondary antibodies as follows; AlexaFluor 488-conjugated goat anti-mouse IgG, AlexaFluor 488-conjugated donkey anti-mouse IgG, AlexaFluor 594-conjugated goat anti-rabbit IgG, and AlexaFluor 594-conjugated donkey anti-goat IgG (1:500; Invitrogen, Paisley, UK). Subsequently, the sections were observed under a confocal microscopy A1Rsi (Nikon, Tokyo, Japan) and a fluorescent microscopy BZ-9000 (Keyence, Osaka, Japan).
KS expression in experimental autoimmune neuritis

H Matsu et al

1. Zhang Z, Zhang ZY, Schluesener HJ. Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol 2009; 183: 3081–3089.

2. Hughes RAC. Systematic reviews of treatment for inflammatory demyelinating neuropathy. J Neurol Neurosurg Psychiatry 2002; 72: 331–339.

3. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30: 131–156.

4. Hahn AF. Experimental allergic neuritis (EAN) as a model for the immune-mediated demyelinating neuropathies. Rev Neurol 1996; 152: 328–332.

5. Hughes RA, Cornblath DR. Guillian-Barre syndrome. Lancet 2005; 366: 1653–1666.

6. Winer JB. Guillian-Barre syndrome. Neurol Pathol 2001; 54: 381–391.

7. Weber CB, Steinke S, Trautmann K, Schluesener HJ. Experimental autoimmun neuritis induces differential microglia activation in the rat spinal cord. J Immunol 2005; 176: 25–31.

8. Zhang Z, Zhang ZY, Fauser U, Schluesener HJ. Mechanical allodynia and spinal up-regulation of P2X4 receptor in experimental autoimmune neuritis rats. Neuroscience 2008; 152: 496–501.

9. Brunn A, Uemöhlen O, Cantov M, Ruiz MS, Miletic H, Schlueter D et al. CD4+ T cells mediate axonal damage and spinal cord motor neuron apoptosis in murine p0106-125-induced experimental autoimmune neuritis. Am J Pathol 2008; 173: 93–105.

10. Johnson-Green P, Dow KE, Ropeile RJ. Characterization of glycosaminoglycans produced by primary astrocytes in vitro. Glia 1991; 4: 314–321.

11. Scott JE, Cummings C, Greiling H, Stuhlfatz HW, Gregory JD, Damien SP. Expression of core proteins and glycosaminoglycans by rotary shadowing and electron microscopy. Int J Biochem 1990; 12: 180–184.

12. Uchiguti K, El-Fasakhany FM, Hor M, Hermesch S, Blink SE, Kansai GS et al. Specificity of N-acetylglucosaminyl-6-O-sulfotransferases in relation to lectin-selected ligand synthesis and tumor-associated enzyme expression. J Biol Chem 2002; 277: 3979–3984.

13. Zhang H, Muramatsu T, Murase A, Yusa S, Uchimura K, Kadoshima K. N-Acetylglucosamine 6-O-sulfotransferase-1 is required for brain keratan sulfate biosynthesis and glial scar formation after brain injury. Glycobiology 2006; 16: 702–710.

14. Jones LL, Tuszynski MH. Spinal cord injury elicits expression of keratan sulphate proteoglycans by microglia, reactive microglia, and oligodendrocyte progenitors. J Neurosci 2002; 22: 4611–4624.

15. Ito Z, Sakamoto K, Imagama S, Matsuyama Y, Zhang H, Hirano K et al. N-Acetylglucosaminyl-6-O-sulfotransferase-1-deficient mice show more functional recovery after spinal cord injury. J Neurosci 2010; 30: 5937–5947.

16. Imagama S, Sakamoto K, Tauchi R, Shiryo R, Ohgomori T, Ito Z et al. Keratan sulfate restricts neural plasticity after spinal cord injury. J Neurosci 2011; 31: 17091–17102.
17. Graeber MB. Changing face of microglia. Science 2010; 330: 783–788.
18. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009; 29: 13435–13444.
19. Mikita J, Dubourdieu-Cassagne N, Deloire MS, Vekris A, Brau M, Raffard G et al. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult Scler 2011; 17: 2–15.
20. Lu MO, Zhu J. The role of cytokines in Guillain-Barre syndrome. J Neurol 2011; 258: 533–548.
21. Jander S, Schroeter M, Fischer J, Stoll G. Differential regulation of microglial keratan sulfate immunoreactivity by proinflammatory cytokines and colony-stimulating factors. Glia 2000; 30: 401–410.
22. Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K et al. Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis 2013; 4: e525.
23. Hirano K, Ohgomori T, Kobayashi K, Tanaka F, Matsumoto T, Natori T et al. Ablation of keratan sulfate accelerates early phase pathogenesis of ALS. PLoS One 2013; 8: e69869.
24. Tauchi R, Imagama S, Natori T, Ohgomori T, Muramoto A, Shinjo R et al. The endogenous proteoglycan-degrading enzyme ADAMTS-4 promotes functional recovery after spinal cord injury. J Neuroinflammation 2012; 9: 53.
25. Tauchi R, Imagama S, Ohgomori T, Natori T, Shinjo R, Ishiguro N et al. ADAMTS-13 is produced by glial cells and upregulated after spinal cord injury. Neurosci Lett 2012; 517: 1–6.
26. Jander S, Stoll G. Downregulation of microglial keratan sulfate proteoglycans coincident with lymphomonocytic infiltration of the rat central nervous system. Am J Pathol 1996; 148: 71–78.
27. Jander S, Stoll G. Strain-specific expression of microglial keratan sulfate proteoglycans in the normal rat central nervous system: inverse correlation with constitutive expression of major histocompatibility complex class II antigens. Glia 1996; 18: 255–260.
28. Ponomarev ED, Veremeenko T, Barteneva N, Kirichevsky AM, Weiner HL. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α–PU.1 pathway. Nat Med 2011; 17: 64–70.
29. Graft JW, Dickson AM, Clay G, McCaffrey AP, Wilson ME. Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem 2012; 287: 21816–21825.
30. Miyamoto K, Oka N, Kawasaki T, Mysake S, Yamamura T, Akiguchi I. New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis. Muscle Nerve 2002; 25: 280–282.
31. Khoroochii R, Owens T. Injury-induced type I IFN signaling regulates inflammatory responses in the central nervous system. J Immunol 2010; 185: 1258–1264.
32. Jin X, Ishii H, Bai Z, Itozue T, Yamashita T. Temporal changes in cell marker expression and cellular infiltration in a controlled cortical impact model in adult male C57BL/6 mice. PLoS One 2012; 7: e41892.
33. Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci USA 2008; 105: 17913–17918.
34. Locatelli G, Wörgetter S, Buch T, Ingold B, Frommer F et al. Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat Neurosci 2012; 15: 543–550.